trending Market Intelligence /marketintelligence/en/news-insights/trending/ihk8batcwu2zagx06njvrg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Bristol-Myers Squibb nabs global rights to PsiOxus' solid tumors treatment

South Korean Multichannel Industry To Survive With Right Strategies

South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities

Mining Exploration Insights: Financing Falls To 8-Month Low In October

ITU Clears The Way For 17.25 GHz Of New mmWave Spectrum For 5G

Bristol-Myers Squibb nabs global rights to PsiOxus' solid tumors treatment

Bristol-Myers Squibb Co. secured exclusive worldwide rights to PsiOxus Therapeutics Ltd.'s NG-348, a preclinical stage oncolytic virus for the potential treatment of solid tumors.

The deal is subject to clearance under the Hart-Scott-Rodino Act.

Bristol-Myers will make a $50 million up-front payment to PsiOxus for the rights and will be solely responsible for global clinical development and commercialization activities for the treatment. The company will also provide PsiOxus funding to support activities related to the preclinical development of the therapy.

PsiOxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sales.

Oncolytic virus therapy utilizes modified viruses such as the adenovirus that selectively replicate within tumor cells and not within normal tissue. Such viruses stimulate an inflammatory response in the tumor microenvironment, resulting in the accumulation of tumor infiltrating lymphocytes.